Rupal S. Bhatt, MD, PhD, discusses the potential identification of a pathway of resistance for PD-L1 in renal cell carcinoma.
Rupal S. Bhatt, MD, PhD
Advertisement
Articles by Rupal S. Bhatt, MD, PhD
Rupal S. Bhatt, MD, PhD, discusses the discovery of HHLA2/KIR3DL3, a novel therapeutic immune checkpoint pathway in renal cell carcinoma.
Advertisement
Latest Updated Articles
Dr. Bhatt on Identification of Immune Checkpoint Pathway in RCCOctober 2nd 2019
Dr. Bhatt on Finding a PD-L1 Pathway of Resistance in RCCOctober 25th 2019
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
3
Five Under 5: Top Oncology Videos for the Week of 9/20
4
FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC
5